The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Full description

Bibliographic Details
Main Authors:	Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Diagnostics
Subjects:	peptide receptor radionuclide therapy PRRT 68Ga-labeled somatostatin analogue 18F-FDG response assessment RECIST
Online Access:	https://www.mdpi.com/2075-4418/10/12/1083

Similar Items

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
by: Fiona Ohlendorf, et al.
Published: (2021-03-01)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
by: Vera G. Megdanova-Chipeva, et al.
Published: (2020-07-01)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
by: Severi S, et al.
Published: (2017-01-01)

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
by: Pashtoon Murtaza Kasi, et al.
Published: (2019-01-01)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
by: Baptiste Camus, et al.
Published: (2021-03-01)

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
by: Daphne M. V. Huizing, et al.
Published: (2020-08-01)

Radionuclide imaging and therapy in patients with neuroendocrine tumors
by: Olga D. Baranova, et al.
Published: (2018-03-01)

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
by: Kjell Oberg, et al.
Published: (2016-09-01)

Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead
by: Stephan Walrand, et al.
Published: (2021-08-01)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
by: Anna Yordanova, et al.
Published: (2020-11-01)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
by: Anna Kathrin Stueven, et al.
Published: (2019-06-01)

Management of Small Bowel Neuroendocrine Tumors
by: Vincent Larouche, et al.
Published: (2019-09-01)

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
by: Buzzoni R, et al.
Published: (2017-10-01)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
by: Starr JS, et al.
Published: (2020-04-01)

Initial clinical evaluation of indigenous90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects
by: Rahul V Parghane, et al.
Published: (2021-01-01)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
by: Thomas Gress, et al.
Published: (2012-02-01)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
by: Beata Kos-Kudła, et al.
Published: (2017-06-01)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
by: Kjell Öberg
Published: (2012-01-01)

68Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients
by: Virginia Liberini, et al.
Published: (2021-01-01)

Clinical Utility of <sup>18</sup>F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis
by: Emmanouil Alevroudis, et al.
Published: (2021-04-01)

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
by: Thorsten Derlin, et al.
Published: (2021-03-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
by: Ström T, et al.
Published: (2019-10-01)

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
by: Erika Grossrubatscher, et al.
Published: (2020-10-01)

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo
by: Franziska Briest, et al.
Published: (2021-01-01)

Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
by: Daleen Geldenhuys, et al.
Published: (2020-10-01)

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
by: Pashtoon M. Kasi, et al.
Published: (2019-01-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
by: Sheila D. Rustgi, et al.
Published: (2021-05-01)

Role of Combined [<sup>68</sup>Ga]Ga-DOTA-SST Analogues and [<sup>18</sup>F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
by: Luciano Carideo, et al.
Published: (2019-07-01)

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
by: G Giuffrida, et al.
Published: (2019-05-01)

Systemic treatment for lung carcinoids: from bench to bedside
by: Mariangela Torniai, et al.
Published: (2019-07-01)

Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons
by: Ralph A. Bundschuh, et al.
Published: (2019-09-01)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
by: Mayank Patel, et al.
Published: (2021-03-01)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of <sup>177</sup>Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
by: Rashmi G. Shah, et al.
Published: (2021-01-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
by: Yuheng Hu, et al.
Published: (2021-05-01)

Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT
by: Anna-Karin Elf, et al.
Published: (2021-04-01)

Lutathera<sup>®</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
by: Ute Hennrich, et al.
Published: (2019-07-01)

Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
by: Beata Polowczyk, et al.
Published: (2020-07-01)

Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved?
by: L. Yu. Morgunov
Published: (2015-06-01)

The Clinico-epidemiologic Characteristics of Iraqi Patients with Neuroendocrine Tumors and Their Response to Long Acting Octreotide
by: Marwah K. Abdulfattah, et al.
Published: (2016-01-01)